🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Incredible to have Daniel Stover, MD, FASCO giving a keynote lecture at the Harvard Breast and Gynecologic Cancer Symposium- what a thoughtful and practical approach to translational research in breast cancer

Thrilled to share work from our MD Anderson Cancer Center IBC team & Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Dana-Farber’s Breast Oncology Center IBC team supported by IBC Research Fdn and Susan G. Komen to validate a new IBC scoring system to improve IBC diagnosis! #thinkibc academic.oup.com/jnci/advance-a…

Incredibly grateful for support from Brigham and Women's Hospital and Mass General Brigham Innovation on a novel strategy the Guerriero Lab Brigham and Women’s Department of Surgery is pioneering to eliminate tumor promoting macrophages in tumors. Eliminating these macrophages should make chemo- and immuno-therapy work better across

Meet Adela Rodríguez Hernández, MD (Adela Rodríguez Hernández)! She joined Dana-Farber from Hospital Clínic in Barcelona @Idibaps. She focuses on #HereditaryCancer and the clinical integration of germline testing to guide prevention and treatment decisions. She is working closely with Dr.

Great presentation on cell cycle inhibitors by Antonio Giordano, MD PhD at the Breast Cancer US Focus Meeting in Boston Dana-Farber’s Breast Oncology Center MD Education VIRGINIA KAKLAMANI

Expert talk on ctDNA by Stefania Morganti breast cancer- we need more data on what to do for pts with MRD in the adjuvant setting Stefania Morganti, MD Dana-Farber’s Breast Oncology Center VIRGINIA KAKLAMANI

Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 highlights the critical need for trimodality therapy for inflammatory breast cancer Dana-Farber’s Breast Oncology Center MD Education VIRGINIA KAKLAMANI

New #JITC article: Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy

Now is oficial Dr. Sara Tolaney will present the primary results of DB09 on June 2nd at Hall D1 at 7:30am #asco25

A superstar translational scientist and clinician Nolan Priedigkeit presents his work on fusions in breast cancer Very innovative work and relevant as we are starting to pick up ESR1 fusions and need to figure out how to approach this Dana-Farber’s Breast Oncology Center

The new ZAP-IT study is evaluating the safety and effectiveness of #Azenosertib (ZN-c3) in combination with carboplatin and pembrolizumab in metastatic #TripleNegativeBreastCancer. For more information call 877-338-7425 or visit: dana-farber.org/clinical-trial… PI: Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 #TNBC

Check out this retrospective observational study recently published in Oncology and Therapy on #OncotypeDX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early #BreastCancer 🔓pubmed.ncbi.nlm.nih.gov/40232579/ Stefania Morganti, MD ​​Ann Partridge MD, MPH Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸

Our 2025 lab retreat!! Always a great day talking about science, brainstorming and celebrating another wonderful year! Farewell Duarte and Jerry heading to graduate programs Carnegie Mellon University and ETH Zurich, and Martin to surgeon-scientist faculty position UniSpitalBaselCH! Brigham and Women's Hospital Department of Urology

So much happening in breast cancer. Join us in July 2025 for two days to make sense of it all. cmecatalog.hms.harvard.edu/breast-cancer-…

Dana-Farber’s Breast Oncology Center is ready for a practice-changing Metastatic Breast Cancer Session at #ASCO25. Here we go!!!

Happening Now #ASCO25 Poster Session 👉AXALAP: Phase Ib study of axatilimab in combination with olaparib in BRCA1/2 and PALB2-associated metastatic HER2-negative #BreastCancer. Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Adela Rodríguez Hernández judy garber Jennifer Guerriero, PhD 📍Abs: TPS1143 | Poster Bd 110b | Jun 2 |

Happening Now! #ASCO25 Poster Session 👉Association between chemotherapy use and clinical outcomes in young BRCA carriers with T1N0 #BreastCancer: Results from an international cohort study. Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Matteo Lambertini, MD PhD Ann Partridge MD, MPH 📍Abs 541 | Poster Bd134 | Jun 2, 9-12 PM CDT

Dream team breast cancer researchers Dana-Farber’s Breast Oncology Center Dana-Farber pioneering advancement therapeutics for patients #bcsm ASCO Sara Tolaney Ann Partridge MD, MPH Harold J. Burstein, MD, PhD, FASCO Nancy Lin, MD Erica Mayer Dr Sarah Sammons Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Ada Waks Heather Parsons Ilana Schlam Elahe Salehi DNP Paolo Tarantino

👏Congratulations to Dana-Farber's Filipa Lynce, MD, FASCO (Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸), recipient of the Advanced Clinical Research Award in #BreastCancer Research from Conquer Cancer, the ASCO Foundation. Dr. Lynce's work will focus on deciphering mechanisms of response to novel therapies in HER2 expressing

🚨 If you're as serious about breast cancer care as Reshma Mahtani, Alan Baik, Antonio Giordano, MD PhD, Stephanie Graff, MD, FACP, FASCO, Claudine Isaacs, Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸, Heather McArthur, MD, MPH, FASCO, Kelly McCann, MD, PhD, Olufunmilayo Olopade, Kristin E. Rojas MD, FACS, FACOG, Dr Sarah Sammons, Rebecca Shatsky, MD, Joyce O'Shaughnessy, MD then you won't miss #PBCCLive25 in DC! It's the